Susan G. Komen @SusanGKomen · 02 Jun 2026
🧬 Sara Hurvitz, MD presents VIKTORIA-1 at #ASCO26: In HR+/HER2- PIK3CA-mutant breast cancer after CDK4/6i, gedatolisib + fulvestrant (with or without palbociclib) doubled progression-free survival vs standard of care (11.1 vs 5.6 months). 🎯 @ASCO https://t.co/tGj6Qorbo6
920Views
11Likes
6Reposts
0Replies
0Quotes
3Bookmarks
Is that a lot?
0.04×vs 100K–1M median21 891 views is typical
0.88%Reachviews ÷ followers
1.85%Engagement rateof viewers reacted